首页> 外文期刊>Frontiers in Immunology >Diagnostic Biomarkers to Diagnose Acute Allograft Rejection After Liver Transplantation: Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies
【24h】

Diagnostic Biomarkers to Diagnose Acute Allograft Rejection After Liver Transplantation: Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies

机译:诊断性生物标记物用于诊断肝移植后急性异体排斥反应:诊断准确性研究的系统评价和荟萃分析

获取原文
           

摘要

Objective: A systematic review and meta-analysis of diagnostic biomarkers for noninvasive diagnosis of acute allograft rejection following liver transplantation. Background: Noninvasive blood and urine markers have been widely explored in recent decades for diagnosing acute rejection after liver transplantation. However, none have been translated into routine clinical use so far due to uncertain diagnostic accuracy, and liver biopsy remains the gold standard. Methods: Systematic literature searches of Medline, Cochrane and Embase were conducted up to February 2019 to identify studies evaluating the use of noninvasive markers in diagnosing allograft rejection following liver transplantation. Meta-analysis was performed using a random effects model with DerSimonian–Laird weighting and the hierarchical summary receiver operating curve. Results: Of 560 identified studies, 15 studies (1,445 patients) met the inclusion criteria. The following markers were tested: acid labile nitroso-compounds (NOx), serum amyloid A protein, procalcitonin, peripheral blood eosinophil count, peripheral blood T-cell activation and interleukin 2 (IL-2) receptor, guanylate-binding protein-2 mRNA, graft-derived cell-free DNA, pi-glutathione S-transferase, alpha-glutathione S-transferase and serum HLA class I soluble antigens. Only eosinophil count was tested in multiple studies, and they demonstrated high heterogeneity ( I ~(2) = 72% [95% CI: 0.5–0.99]). IL-2 receptor demonstrated the highest sensitivity (89% [95% CI: 0.78–0.96]) and specificity (81% [95% CI: 0.69–0.89]). Conclusion: IL-2 receptor expression demonstrated the highest diagnostic accuracy, while the peripheral eosinophil count was the only marker tested in more than one study. Presently, liver biopsy remains superior to noninvasive diagnostic biomarkers as most studies exhibited inferior designs, hindering possible translation into clinical application.
机译:目的:对肝移植后急性同种异体排斥反应的无创诊断进行诊断性生物标志物的系统评价和荟萃分析。背景:近几十年来,无创血液和尿液标记物已广泛用于诊断肝移植后的急性排斥反应。然而,由于不确定的诊断准确性,到目前为止,尚未将其转化为常规临床应用,肝活检仍是金标准。方法:截至2019年2月,对Medline,Cochrane和Embase进行了系统的文献检索,以鉴定评估无创标记物在肝移植后诊断同种异体移植排斥反应中使用的研究。使用DerSimonian–Laird加权和分层汇总接收器操作曲线的随机效应模型进行荟萃分析。结果:在560项确定的研究中,有15项研究(1,445例患者)符合纳入标准。测试了以下标记:酸不稳定的亚硝基化合物(NOx),血清淀粉样蛋白A蛋白,降钙素,外周血嗜酸性粒细胞计数,外周血T细胞活化和白介素2(IL-2)受体,鸟苷结合蛋白2 mRNA ,源自移植物的无细胞DNA,pi-谷胱甘肽S-转移酶,α-谷胱甘肽S-转移酶和血清HLA I类可溶性抗原。在多项研究中仅对嗜酸性粒细胞计数进行了测试,结果表明它们具有很高的异质性(I〜(2)= 72%[95%CI:0.5-0.99])。 IL-2受体显示出最高的敏感性(89%[95%CI:0.78–0.96])和特异性(81%[95%CI:0.69–0.89])。结论:IL-2受体表达显示出最高的诊断准确性,而外周嗜酸性粒细胞计数是一项以上研究中唯一测试的标志物。目前,肝活检仍优于非侵入性诊断生物标志物,因为大多数研究显示其设计较差,阻碍了其向临床应用的转化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号